Use the Back button in your browser to see the other results of your search or to select another record.
Detailed Search Results
| Feasibility and clinical potential of exercise interventions during neoadjuvant chemoradiotherapy in patients with esophageal and rectal cancer [with consumer summary] |
| Mast IH, Gootjes EC, Rutten H, den Hartogh MD, Brouwer CG, Nagtegaal ID, van der Post RS, Hopman MTE, Heuvel BvD, Rosman C, de Wilt JHW, Klarenbeek BR, Buffart LM |
| Journal of Sport and Health Science 2025 Dec;14:101060 |
| clinical trial |
| This trial has not yet been rated. |
|
BACKGROUND: Exercise during neoadjuvant chemoradiotherapy (NCRT) has potential to mitigate treatment-related declines in physical fitness, and to improve clinical outcomes, including toxicity and tumor response. However, optimal frequency and timing of exercise remains to be determined. Therefore, this pilot trial aimed to assess feasibility of 2 different exercise interventions during NCRT in patients with esophageal and rectal cancer and to evaluate potential clinical effects. METHODS: Patients were randomized into 1 of 3 study arms during NCRT: (a) 30-min aerobic exercise in-hospital within 1h prior to each radiotherapy fraction (ExPR), (b) two 60-min supervised combined aerobic and resistance exercise sessions per week (AE plus RE), and (c) usual care (UC). Feasibility was assessed by examining participation rate and exercise adherence. Intervention effects on physical fitness, health-related quality of life, treatment-related toxicity, and tumor response in patients with esophageal cancer were explored using regression analyses and 85% confidence intervals (85% CI). RESULTS: Thirty-seven patients with esophageal cancer (participation rate: 45%) and 2 patients with rectal cancer (participation rate: 14%) were included. Median session attendance was 98% (interquartile range (IQR) 96 to 100) in the ExPR and 78% (IQR 33 to 100) in the AE plus RE group. We found clinically relevant benefits of exercise on maximal oxygen uptake (VO2max) (ExPR: beta 9.7mL/kg/min, 85% CI 6.9 to 12.6; AE plus RE: beta 5.6mL/kg/min, 85% CI 2.6 to 8.5) and treatment-related toxicity (ExPR: beta -2.8, 85% CI -5.4 to -0.2; AE plus RE: beta -2.6, 85% CI -5.3 to 0.0). Additionally, good tumor response was found in 70% in AE plus RE and ExPR versus 55% in UC (OR 1.9, 85% CI 0.5 to 7.7). CONCLUSION: Starting prehabilitation during NCRT is feasible, can increase starting fitness of traditional pre-surgical programs, and has potential to improve clinical outcomes.
|
The database was last updated on 2 February 2026 (this includes records added or amended since 5 January 2026). The next update is planned for 2 March 2026. The total number of records on the database is 67,267.